scPharmaceuticals Inc (NASDAQ:SCPH) Q4 2023 Results Conference Call March 13, 2024 4:30 PM ET Company Participants PJ Kelleher - LifeSci Advisors John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President, Commercial Rachael Nokes - Chief Financial Officer John Mohr - Senior Vice President of Clinical Development & Medical Affairs Conference Call Participants Rosa Chen - Leerink Partners Stacy Ku - TD Cowen Douglas Tsao - H. C. Wainwright Chase Knickerbocker - Craig-Hallum Naz Rahman - Maxi ...

- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38293 SCPHARMACEUTICALS INC. (Exact name of registrant as specified in its Charter) Delaware 46-5184075 (State or other jurisdictio ...

scPharmaceuticals Inc (NASDAQ:SCPH) Q3 2023 Earnings Call Transcript November 8, 2023 4:30 PM ET Company Participants PJ Kelleher - LifeSci Advisors John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President, Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Nik Gasic - Leerink Partners Douglas Tsao - H.C. Wainwright Naz Rahman - Maxim Group Chase Knickerbocker - Craig-Hallum Capital Group Operator Thank you for standing by. This is the conference operator. Wel ...

Corporate Presentation November 2023 Disclaimer This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our launch and commercialization plans, our clinical results and other future conditions. All ...

1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38293 SCPHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 46-5184075 (State or other jurisdiction ...

scPharmaceuticals Inc. (NASDAQ:SCPH) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants PJ Kelleher - Investor Relations John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President, Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Glen Santangelo - Jefferies Stacy Ku - TD Cowen Doug Tsao - H.C. Wainwright Naz Rahman - Maxim Group Operator Good day and welcome to the scPharmaceuticals Second Quarter 2023 Earnings Conference Call. Al ...

1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38293 SCPHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 46-5184075 (State or other jurisdiction of ( ...

1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38293 SCPHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 46-5184075 (State or other jurisdiction of ...

scPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2022 Earnings Conference Call March 22, 2023 4:30 PM ET Company Participants PJ Kelleher - LifeSci Advisors John Tucker - CEO Rachael Nokes - CFO Steve Parsons - SVP, Commercial Conference Call Participants Glen Santangelo - Jefferies Nik Gasic - SVB Securities Stacy Ku - Cowen Douglas Tsao - H.C. Wainwright Nazibur Rahman - Maxim Group Greetings, and welcome to the scPharmaceuticals Fourth Quarter and Full Year 2022 Earnings Conference Call. [Operator Instructions] A ...

- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from- to Commission File Number 001-38293 SCPHARMACEUTICALS INC. (Exact name of registrant as specified in its Charter) Delaware 46-5184075 (State or other jurisdicti ...